Nabriva Therapeutics, which is developing a novel antibiotic for bacterial pneumonia, raised $92 million by offering 9 million ADSs at $10.25, below the downwardly revised price of $10.50. The company originally planned to offer 6 million ADSs at $15 to $17. Insiders plan to buy $42 million on the IPO, compared to $60 million in the revised terms and $50 million originally. Nabriva Therapeutics plans to list on the Nasdaq under the symbol NBRV. Nabriva Therapeutics initially filed confidentially on 5/14/2015. Leerink Partners and RBC Capital Markets acted as lead managers on the deal.
